TO-208 Clinical Pharmacology Study- Open-Label Study to Evaluate the Safety, Efficacy, and Plasma Concentrations of TO-208 in Patients Aged 2 Years and Older with Molluscum Contagiosum -

Start Date27 Jul 2023

Sponsor / Collaborator-

NCT05597098

/ RecruitingEarly Phase 1

Investigation of the Distinct Mechanisms Involved in Inflammatory Resolution Between Healthy Men and Women: RESOLVE-SEX

Important differences exist between sexes in incidence, disease patterns and outcomes in coronary artery disease that is not well understood. It is likely that key differences in the underlying biological mechanism, in particular in inflammatory responses, play a part in underpinning these differences. Previous evidence demonstrates that healthy females appear to be more adept at resolving inflammation compared to healthy males. Since inflammation is thought to be a key initiating phenomenon in coronary artery disease the investigators will examine the differences in inflammatory resolution between the sexes in healthy volunteers.

Start Date12 Dec 2022

Sponsor / Collaborator

Queen Mary University of London

NCT03981822

/ CompletedPhase 2

A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts

This is a Phase 2, double-blind, placebo-controlled study to determine the dose regimen, safety, tolerability, and efficacy of VP-102 in subjects with External Genital Warts (EGW). This study is divided into two parts (Part A and Part B). Increasing durations of skin exposure to study drug (VP-102 or placebo) will be evaluated in three treatment groups prior to progressing to enrollment in Part B. Part A & B will enroll a approximately 108 subjects completing 4 treatment applications every 21 days and continuing with follow-up assessments at Day 84, 112 and 147.

Start Date25 Jun 2019

Sponsor / Collaborator

Verrica Pharmaceuticals, Inc.

[+3]

100 Clinical Results associated with Cantharidin

100 Translational Medicine associated with Cantharidin

100 Patents (Medical) associated with Cantharidin

1,653

Literatures (Medical) associated with Cantharidin

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Exploration of material basis: Chemical composition profile and metabolic profile in Xiao Jianzhong Granules

Article

Author: Li, Caihong ; Wang, Hongjin ; Zhou, Xuanxuan ; Zheng, Ling ; Wang, Jiaxue ; Sun, Lixin

Xiao Jianzhong Granules (XJZG), a well-known traditional prescription with protective effects on the gastric mucosa, as documented in the Treatise on Typhoid and Miscellaneous Diseases. Clinical studies have proven that XJZG exhibits significant anti-colitis properties and effectively alleviates duodenal ulcers. However, despite its clinical popularity, comprehensive studies on its chemical composition and in vivo metabolism remain limited. In the present study, gas chromatography coupled with mass spectrometry (GC-MS) and ultra-high-performance liquid chromatography coupled with Q-Exactive Orbitrap mass spectrometry (UHPLC Q-Exactive Orbitrap MS) were used to analyze the chemical composition of XJZG, while it is in vivo metabolic profile was further assessed with UHPLC Q-Exactive Orbitrap MS. Additionally, ultra-high-performance liquid chromatography coupled with triple quadrupole mass spectrometry (UHPLC-MS/MS) was utilized to quantify its primary components. As a result, a total of 51 volatiles were characterized by GC-MS, and 139 compounds were characterized by UHPLC Q-Exactive Orbitrap MS in vitro. In addition, 51 prototype components and 133 metabolites were characterized in vivo. Notably, 5 new compounds were discovered in this process. The main metabolic reactions included oxidation, reduction, hydrolysis, glucuronidation, and sulfate esterification. In quantitative analysis, 17 components were determined and successfully applied for detection by UPLC-MS/MS in multiple reaction monitoring mode. The quantitative methods were validated and met the requirements. Through multivariate statistical analysis, 6 components were selected as potential quality markers for XJZG based on PCA and OPLS-DA. Additionally, our study provides supplementary chemical evidence to further elucidate the material basis of XJZG.

01 Jun 2025·FOOD CHEMISTRY

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

Author: Huang, Xia ; Wan, Yuping ; Shi, Peiyu ; Wu, Wenlin ; Xiao, Quanwei ; Liu, Shiyao ; Guo, Tianrong ; Zhang, Min ; Xia, Bing ; Zhou, Yan ; Chen, Xiaoqi

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

01 May 2025·FISH & SHELLFISH IMMUNOLOGY

Bioinformatic and gene expression analysis of the somatostatin/cortistatin gene family in the gilthead seabream (Sparus aurata)

Article

Author: Cuesta, Alberto ; Esteban, María Ángeles ; Serna-Duque, Jhon A ; Campos-Sánchez, Jose Carlos ; Guardiola, Francisco A

Somatostatin (SST) and cortistatin (CST) are neuromodulators with distinct expression patterns and functions. While SST and CST have been extensively studied in mammalian central nervous system (CNS) and immune system, their roles in teleost fish remain poorly explored due to evolutionary emergence of multiple SST paralogous genes. This study aimed to identify SST isoforms in gilthead seabream (Sparus aurata) and assess their transcriptional levels. Phylogeny and synteny analyses reclassified the six SST genes and proteins as SST1, SST3, SST3-like, SST4, SST5, and SST6. The protein sequences showed high conservation, except for an additional region upstream of the SST3-like protein's leader region. Evolutionary differences were mainly due to specific amino acid residue changes in the mature peptide. Genetic analyses revealed constitutive expression of five genes (sst1, sst3, sst5, sst4 and sst6) in all studied organs, except for sst3 in the heart, liver, and blood. The highest expression of sst1, sst3, sst4 and sst6 genes occurred in the brain's forebrain, while sst5 was most expressed in the heart. However, sst4 exhibited very low basal expression across all analysed tissues. In vitro, λ-carrageenan and cantharidin upregulated sst6 transcription in head kidney leucocytes (HKLs), indicating a potential anti-inflammatory role similar to mammalian CST. Additionally, sst5 expression was downregulated during the innate cell-mediated cytotoxic response, suggesting a regulatory role. These findings provide insights into the SST/CST gene family in gilthead seabream, necessitating gene and protein reclassification, and underscore their significant neuroendocrine and immune system functions, relevant for teleost research.

News (Medical) associated with Cantharidin

21 Jan 2025

·www.globenewswire.com

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters highlight the safety data, tolerability data, and antitumor efficacy data of VP-315 for the treatment of basal cell carcinoma as determined by histological clearance WEST CHESTER, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the presentation of three posters that were presented at the 2025 Winter Clinical Dermatology Conference, which was held from January 17-19, in Miami, Florida. The posters featured clinical data from Part 2 of the Phase 2 study (the “Study”) of the Company’s novel oncolytic peptide, VP-315, for the treatment of basal cell carcinoma (“BCC”). Verrica presented a poster titled “Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC)” while encore presentations of two additional posters (titled “Results of a Phase 2 Multicenter Study Evaluating the Safety and Tolerability of VP-315, an Investigational therapy for Basal Cell Carcinoma” and “Results of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational Therapy for Basal Cell Carcinoma”) were also made at the conference. The posters included safety and histologic clearance data from 82 patients with up to two target BCC tumors (a total of 91 tumors) in Part 2 of the Study evaluating VP-315 for the treatment of BCC, including patients with tumors on the head and neck. Part 2 of the Study was designed to explore dosing regimens to help Verrica identify the recommended regimen for a Phase 3 study program. Approximately 51% of tumors treated in the Study achieved complete histological clearance, while those patients with a residual tumor achieved, on average, approximately 71% reduction in tumor size. There were no Treatment Related Serious Adverse Events, and most Treatment Related Adverse Events were mild to moderate. In the newly-presented poster, Verrica conducted a post-hoc analysis of the data from the Study and announced a Calculated ORR of 97%, defined as the percentage of study subjects who do not demonstrate disease progression and who experience at least a 30% level of tumor reduction along with partial or complete response following treatment The Company still expects genomic and T-cell (immune response) data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine the next steps for the development of VP-315 for the treatment of BCC. “We remain highly encouraged by the positive preliminary topline results from Part 2 of the Phase 2 study for VP-315, which we believe support a potential change in the treatment paradigm for patients with basal cell carcinoma,” said Dr. Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica. “We believe these results will support the use of VP-315 as a potential first line therapy for use in both primary and neoadjuvant settings, and that VP-315 could provide the millions of basal cell carcinoma patients diagnosed in the United States each year with a non-surgical alternative to painful, invasive surgical treatments. We believe that VP-315 could represent a multi-billion-dollar commercial opportunity for Verrica. We look forward to our discussions with the FDA about designing a development path forward for VP-315 in 2025.” About the Phase 2 Study of VP-315The Study is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven BCC. The study enrolled 92 adult subjects with a histological diagnosis of BCC in at least one eligible target tumor. For additional information about this clinical trial, please visit clinicaltrials.gov, identifier NCT05188729. About VP- 315VP-315 is a potential first-in-class oncolytic chemotherapeutic peptide immunotherapy administered directly into a tumor to induce immunogenic cell death and thereby unleashing a broad spectrum of tumor antigens for T cell responses, which may offer a non-surgical option for patients suffering from skin cancer. The technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Verrica holds an exclusive worldwide license to develop and commercialize VP-315 for certain dermatologic oncology indications, including non-metastatic melanoma and non-metastatic merkel cell carcinoma, and intends to focus initially on basal cell and squamous cell carcinomas as the lead indications for development. VP-315 has demonstrated positive tumor-specific immune cell responses in multi-indication Phase 1/2 oncology trials. About Basal Cell CarcinomaBasal cell carcinoma is the most common form of cancer in the United States, and its incidence is rising worldwide. There are approximately 3-4 million diagnoses of basal cell carcinoma in the U.S. each year, with a high unmet need for new treatment options. Basal cell carcinoma is generally treated with invasive surgery to remove the tumor, which can cause pain, infection, bleeding and scarring. About Verrica Pharmaceuticals Inc. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements concerning the potential of VP-315, the Company’s research, development and regulatory plans for VP-315, the timing of the Company’s planned clinical trials for VP-315 and reporting data from the Company’s clinical trials, and the potential market size opportunity for the treatment of basal cell carcinoma. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control and uncertainties that are described in Vernica’s Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: info@verrica.com Investors: Kevin GardnerLifeSci Advisorskgardner@lifesciadvisors.com Chris CalabreseLifeSci Advisorsccalabrese@lifesciadvisors.com

Clinical ResultPhase 2License out/inImmunotherapyDrug Approval

20 Dec 2024

·www.globenewswire.com

Verrica Provides Business and Operational Update

-- Dispensed applicator units in the fourth quarter of 2024 have exceeded the complete prior quarter even with significant cost reductions in sales and operational infrastructure -- Observed significant reduction in YCANTH distributor inventory levels -- New single applicator configuration for YCANTH® expected to be available in the first quarter of 2025 to help meet growing product demand, reduce acquisition costs for physician practices and expand distribution and patient access -- Continue to advance pipeline of product candidates in common warts and basal cell carcinoma WEST CHESTER, Pa., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a business and operational update outlining the significant progress being made with respect to the new commercial strategy for YCANTH, Verrica’s lead product for the treatment of molluscum contagiosum (“molluscum”). “Over the last several weeks since our November common stock offering, we have made significant progress across a number of key initiatives to help drive demand for YCANTH,” said Jayson Rieger, PhD MBA, President and Chief Executive Officer of Verrica. “First and foremost, we are executing effectively on our previously announced commercial strategy for YCANTH, as evidenced by achievement of fourth quarter dispensed applicator units already surpassing dispensed applicator units in the prior quarter. We are growing the YCANTH business while implementing highly targeted cost management initiatives to prioritize spend that creates value and reducing or eliminating inefficient and unnecessary expenses. We are also pleased to note a significant reduction in YCANTH inventory levels from our distribution partners.” Dr. Rieger continued, “We are responding to the growing patient demand for YCANTH by increasing our distribution capabilities, making YCANTH available to more dermatologists and pediatricians through our previous distribution channels as well as through local independent pharmacies. Furthermore, we expect to provide a single applicator packaging configuration for YCANTH in the first quarter of 2025, which we anticipate will provide an added level of convenience for our independent and specialty pharmacy network. We also expect that the single applicator packaging will facilitate initial purchases of the product by health care providers who prefer same day treatment for patients by requiring significantly less cash outlay under our buy-and-bill distribution model. Finally, we expect this new packaging may increase patient access by providing added optionality to buying groups, hospitals and government entities for including YCANTH on formulary to service their patients. “As we enter 2025, we are excited about the opportunities that lie ahead for our company. As noted, we are already seeing favorable changes in the demand dynamics for YCANTH in response to our more focused and disciplined commercial strategy. Our recent financing also helped strengthen our balance sheet, while our ongoing efforts to improve Verrica’s operational efficiencies will help preserve our capital resources.” Dr. Rieger concluded, “We also believe that our pipeline opportunities provide a tremendous source of potential upside for our company. Together with our development partner, Torii Pharmaceutical, we continue to advance YCANTH (referred to as TO-208 in Japan) for the treatment of common warts, which represents the opportunity to address the single largest unmet medical need in dermatology. Additionally, encouraging preliminary data from our Phase 2 study suggests that our oncolytic peptide, VP-315, may have the potential to become a new and differentiated treatment approach for basal cell carcinoma. In summary, we have made significant progress over a short period of time, and Verrica is becoming a more focused and efficient commercial-stage company.” About YCANTH® (VP-102)YCANTH® is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. YCANTH® is the first and only commercially available product approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. Approval of YCANTH® was based upon the positive results from two Phase 3 clinical trials in approximately 500 patients which demonstrated that YCANTH® was a safe and effective therapeutic for the treatment of molluscum. Approximately 228 million lives are eligible to receive YCANTH® covered by insurance. YCANTH® is available to all patients with and without insurance coverage for $25 per treatment, and further financial assistance is available for patients in need. Please visit YCANTHPro.com for additional information. YCANTH® should only be administered by a trained healthcare professional. YCANTH® is not for home use. About Verrica Pharmaceuticals Inc. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include statements about the availability of Verrica’s single applicator packaging configuration and the benefits of such configuration, the commercialization of YCANTH, cost management initiatives and preservation of capital resources, and the clinical development and benefits of Verrica’s product candidates, including YCANTH (VP-102). These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the proposed public offering and other risks and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2023, Verrica’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and other filings Verrica makes with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise. FOR MORE INFORMATION, PLEASE CONTACT: Investors: Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com Chris Calabrese LifeSci Advisors ccalabrese@lifesciadvisors.com

Phase 3License out/inPhase 2Drug Approval

09 Dec 2024

·www.globenewswire.com

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Verrica’s Compensation Committee granted David Zawitz, Verrica’s new Chief Operating Officer, a nonqualified stock option to purchase 950,000 shares of its common stock under the Company’s Inducement Plan, effective December 9, 2024. The stock option was granted as a material inducement to Mr. Zawitz’s employment with Verrica in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Verrica (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with Verrica, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The option award will have an exercise price equal to the closing price of Verrica’s common stock on December 9, 2024. The option award will vest and become exercisable as to 1/8th of the shares on the date that is six months following Mr. Zawitz’s start date, and 1/48th of the shares each month thereafter on the same day of the month as the start date, subject to Mr. Zawitz’s continuous service with Verrica on such vesting dates. The option award is subject to the terms and conditions of the Inducement Plan, and the terms and conditions of a stock option agreement covering the grant. About Verrica Pharmaceuticals Inc. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com. FOR MORE INFORMATION, PLEASE CONTACT: Investors: Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com Chris Calabrese LifeSci Advisors ccalabrese@lifesciadvisors.com

License out/in

100 Deals associated with Cantharidin

External Link

KEGG	Wiki	ATC	Drug Bank
D11745	Cantharidin	D11AF	DB12328

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Molluscum Contagiosum	United States	Verrica Pharmaceuticals, Inc.	21 Jul 2023
Condylomata Acuminata	China	Hainan Huiyuantang Pharmaceutical Co Ltd	10 Jul 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


GlobeNewswire Manual	Phase 3	Molluscum Contagiosum	-	TO-208	fxnwprkoch(ejrisqacna) = statistically significant versus placebo wdthpcyaak (nhvuvdapvn )	Positive	15 Dec 2023
				Placebo
NCT03377803 \| NCT03377790 (FDA) Manual	Phase 3	Molluscum Contagiosum	528	YCANTH (Trial 1)	fuyxvktxje(jtfgkotbar) = psjipaxvfc avugijrvpa (cfrtrdnzzu ) View more	Positive	21 Jul 2023
				Vehicle (Trial 1)	fuyxvktxje(jtfgkotbar) = ooencezclv avugijrvpa (cfrtrdnzzu ) View more
NCT03377803 (CAMP-2, CTgov)	Phase 3	Molluscum Contagiosum	262	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	agaekguone = behvexacml qyepvsfoxy (rpdsvmtrvy, bwbwyeryei - jttixsfwiq) View more	-	14 Dec 2021
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	agaekguone = xzmvmswsxn qyepvsfoxy (rpdsvmtrvy, njgpcclpcq - vumkoeehxg) View more
NCT03377790 (CAMP-1, CTgov)	Phase 3	Molluscum Contagiosum	266	VP-102 - Cantharidin, Topical Film Forming Solution (VP-102)	lqmkrferzd = kjnudeuafh nptrqfnpfk (euznxyjtos, vkqcqmdkeh - fyujdrxkop) View more	-	14 Dec 2021
				Placebo -Topical Film Forming Solution without VP-102 (Placebo)	lqmkrferzd = otsvfojrgd nptrqfnpfk (euznxyjtos, spyoesiixm - uhfnalvutr) View more
NCT03981822 (Pubmed \| Am J Clin Dermatol) Manual	Phase 2	Condylomata Acuminata	-	VP-102	iweguqcufa(oncsmepvaf) = wemcjmsuyn vyvtvnjmcd (vbetdrblty ) View more	Positive	01 Nov 2021
				Placebo	iweguqcufa(oncsmepvaf) = iwdfqfnxso vyvtvnjmcd (vbetdrblty ) View more
NCT03487549 (COVE-1, Pubmed) Manual	Phase 2	Warts	56	VP-102 (Cohort 1)	llahkphoaj(hbmrqjdbav) = dcqxgcqshu qyjeqkezrf (mjzagriryv )	Positive	01 Oct 2021
				VP-102 (Cohort 2)	llahkphoaj(hbmrqjdbav) = xoqpcidgix qyjeqkezrf (mjzagriryv )
NCT03487549 (COVE-1, CTgov)	Phase 2	Warts	56	VP-102 cantharidin+VP-102 (Cohort 1)	irlzjrauoh = sxzpugvdjn trqkrcbpvo (ggzwdepoit, ximmgvryqv - kvblcxuife) View more	-	01 Sep 2021
				VP-102 Cantharidin+VP-102 (VP-102 - Cohort 2)	zmeenfaera = rrhdraucjk mvbqmwqbjx (rypzndawki, frkdfpqzdy - cllodoowwx) View more
NCT03186378 (CTgov)	Phase 2	Molluscum Contagiosum	33	VP-102 with applicator (Exposure Group)	hlygvweybc = jblthiefvb zfdlourlhc (vticlixxhz, ocrltoxgpn - pbpedzsgxx) View more	-	09 Aug 2021
				VP-102 with applicator (Standard Group)	hlygvweybc = kdozbyrcje zfdlourlhc (vticlixxhz, qaowhqtcym - qdlgcvvqtd) View more
NCT03377803 \| NCT03377790 (Pubmed \| Am J Clin Dermatol)	Phase 3	Molluscum Contagiosum	-	Vehicle	xqdirmbrif(ixuygwhglz) = lfuradpinl dzbvrhxhvz (zumcimlkcf )	-	18 Feb 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis